Merck KGaA

Biopharma, Innovation & Entrepreneurship Incubator

 Darmstadt, Germany

About Merck KGaA - Innovation

A company that is synonymous with innovation

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions.

We are committed to making great things happen through innovations. Our company has approximately 4,700 R&D professionals worldwide. Thus, more than 1 out of 10 employees discovers and develops innovations that will help people to live a better life. Global R&D hubs of our businesses are strategically located on three continents.

Location of the Research and Innovation Centers
 United States
 South Corea
 United Kingdom
Research Areas
Healthcare Biopharma Allergopharma Consumer Health Life Sciences Performance Materials
Organization Website
Organization Type
Large Enterprise
Year Founded
Darmstadt, Germany
Merck KGaA

Technologies for Licensing (5)

Technology for Lysophosphatidic Acid (LPA) Receptor antagonists

Merck has developed and patented the results of its intense R&D activities for the identification of small organic molecules as antagonists to certain LPA receptors (LPAR1, -R2, -R3). Herein described are LPA-R2 receptor selective inhibitors. Based upon a rational screening cascade established, comp[…]

Novel Pharmaceutical Salt Forming Counterions with Increased Dissolution Rates and Supersaturation

One of the major obstacles in developing promising New Chemical Entities (NCEs) as Active Pharmaceutical Ingredients (APIs) is their low solubility and therefore poor bioavailability. Merck has developed a novel class of salt forming anions as counter-ions for protonated free base APIs which result[…]

Technology for Serum and Glucocorticoid regulated kinase (SGK) inhibitors

Merck KGaA, Darmstadt, Germany, has developed and patented the results of its intense R&D activities for the identification of small organic molecules as SGK1 inhibitors. Based upon a rational screening cascade established, compounds have been identified and characterized with regard to their specif[…]

Selective Autotaxin Inhibitors: a new therapeutic option for CNS diseases, psychiatric and eating disorders

Recent findings (IP protected) reveal a substantial role for Autotaxin (ATX) in context of several biological effects at the synaptic cleft which are indicating a critical role in CNS disorders. This opens new therapeutic potential for ATX inhibitors. Merck KGaA Darmstadt, Germany has developed a[…]

The use of pads or capsules containing coffee grounds or tea leafs for the storage and generation of fresh, high quality hot beverages is a convenient and already well established technology. Numerous devices and different set ups are on the market, the technology of which could also be used to extr[…]

Legal Disclamer

Licensing Opportunties

We are currently seeking best-in-class collaboration partners for the licesing opportunities listed below. You can contact us for currently available technology offers by browsing the listed entries.

Contact Process

Are you interested in one of the offers listed?

Submit your request for information and Merck’s Open Innovation staff member will get in contact with you. Please provide as much detailed information as possible by using the online template available on each of the Technology Offers listed in order to facilitate the contact process.

Need Support?

Contact us if you need support to submit your request for information to Merck KGaA.

Share this site